Curasight is active in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio includes, for example, research and development within Positron Emission Tomography (PET) and related ancillary services. The business is operating with the largest presence within Scandinavia. Curasight is headquartered in Copenhagen.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Andreas Kjær | 30,24 | 30,24 | 2023-12-31 |
| UK Curacap ApS | 19,46 | 19,46 | 2024-06-14 |
| Carsten Haagen Nielsen | 12,11 | 12,11 | 2023-12-31 |
| Jacob Madsen | 4,57 | 4,57 | 2023-12-31 |
| Lars Trolle | 2,95 | 2,95 | 2023-12-31 |
| Chr. Olesen Holding A/S | 2,01 | 2,01 | 2024-06-14 |
| Gerhard Dal | 0,33 | 0,33 | 2024-06-14 |
| Per Falholt | 0,33 | 0,33 | 2023-12-31 |
| Johan Stein | 0,20 | 0,20 | 2024-06-14 |
| Charlotte Vedel | 0,20 | 0,20 | 2023-12-31 |
2025-02-20 Bokslutskommuniké 2024
